Our ambition is to develop drug candidates that have the potential to transform cancer treatment. We do so by leveraging the success of our partnered assets and continuing to invest in our novel proprietary pipeline and technology platforms.

By 2025, our vision is that our own product will have transformed cancer treatment and we will have a robust pipeline of next-generation antibodies.

Founded in Copenhagen, Denmark in 1999, Genmab A/S’s ordinary shares are listed on the Nasdaq Copenhagen A/S under the ticker symbol GMAB and are traded as part of the OMXC25. Genmab’s American Depositary Shares issued under the ADR Program are listed in the U.S. on the Nasdaq Global Select Market under the ticker symbol GMAB, and the shares are included in the NASDAQ Biotechnology Index (Nasdaq: NBI).